The discovery is a demonstration of how AI could dramatically improve the slow and costly search for new antimicrobial medicines, as bacteria and other microbes continue to evolve resistance to our current suite of drugs.
Survival analysis is central to clinical oncology. Modern cancer studies can now measure gene activity in single cells from a patient’s tumor and link this information to how long patients live.
UVA’s Nikolay V. Dokholyan, PhD, and colleagues have developed a suite of artificial intelligence-powered tools, called YuelDesign, YuelPocket and YuelBond, that work together to transform how new drugs are created.
The study was published in JCO Clinical Cancer Informatics, a journal from the American Society of Clinical Oncology.
This report offers a comprehensive analysis of the EU27 digital health landscape, combining market intelligence, stakeholder insights and economic modelling to inform future policy and investment.
The first part of the report provides a detailed overview of the EU digital health technology market. It identifies the key drivers, barriers, and structural characteristics of the European digital health ecosystem, including vendor distribution, market fragmentation, maturity levels of different technology domains, and the roles of providers, regulators, and investors. The analysis highlights strong growth perspectives for the EU digital health market, where Artificial Intelligence stands out as a key technology.
The research, led by Anglia Ruskin University (ARU) in collaboration with Cranfield University, the University of Portsmouth, and Intelligent Omics Ltd, and published in Frontiers in Digital Health, used lifestyle and health data from 19,774 UK adults in the UK Biobank, tracked for up to 17 years.